1
|
Jumagaliyeva MB, Ayaganov DN, Abdelazim IA, Saparbayev SS, Tuychibaeva NM, Kurmambayev YJ. Relation between Guillain-Barré syndrome and Covid-19: Case-Series. J Med Life 2023; 16:1433-1435. [PMID: 38107719 PMCID: PMC10719799 DOI: 10.25122/jml-2023-0275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 08/27/2023] [Indexed: 12/19/2023] Open
Abstract
Approximately two-thirds of the Guillain-Barré syndrome (GBS) cases are preceded by upper respiratory tract infection or enteritis. There has been previous documentation of a clear association between Covid-19 and GBS. Covid-19 can affect the nervous tissue either through direct damage or through triggering a host immune response with subsequent development of autoimmune diseases such as GBS. Covid-19 can affect the host`s immune system through the activation and interaction of the T-and B-lymphocytes with subsequent production of antibodies that cross-react with the gangliosides. Depending on the nature of the neuronal autoimmune destruction, the affected individual may have either a demyelinating or axonal subtype of GBS. These subtypes differ not only in symptoms but also in the likelihood of recovery. This report presents two cases of GBS that developed after the respiratory symptoms of Covid-19. Their neurological features indicated demyelination, axonal damage, irritation of spinal nerve roots, and impaired sensory and motor transmission with additional facial nerve palsy in the second-studied case. This case report highlights the relationship between GBS and Covid-19 infection.
Collapse
Affiliation(s)
| | | | - Ibrahim Anwar Abdelazim
- Department of Obstetrics and Gynecology, Faculty of Medicine Ain Shams University, Cairo, Egypt
| | | | | | | |
Collapse
|
2
|
LoRusso S. Disorders of the Cauda Equina. Continuum (Minneap Minn) 2021; 27:205-224. [PMID: 33522743 DOI: 10.1212/con.0000000000000903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE OF REVIEW Cauda equina dysfunction (often referred to as cauda equina syndrome) is caused by a diverse group of disorders that affect the lumbosacral nerve roots. It is important to recognize dysfunction of the cauda equina quickly to minimize diagnostic delay and lasting neurologic symptoms. This article describes cauda equina anatomy and the clinical features, differential diagnosis, and management of cauda equina disorders. RECENT FINDINGS The diagnosis of disorders of the cauda equina continues to be a challenge. If a compressive etiology is seen, urgent neurosurgical intervention is recommended. However, many people with clinical features of cauda equina dysfunction will have negative diagnostic studies. If the MRI is negative, it is important to understand the diagnostic evaluation and differential diagnosis so that less common etiologies are not missed. SUMMARY Cauda equina dysfunction most often occurs due to lumbosacral disk herniation. Nondiskogenic causes include vascular, infectious, inflammatory, traumatic, and neoplastic etiologies. Urgent evaluation and surgical intervention are recommended in most cases of compressive cauda equina syndrome. Other types of treatment may also be indicated depending on the etiology.
Collapse
|
3
|
Waheed W, Tandan R, Bazylewicz M. Nerve root enhancement in Guillain-Barré syndrome. Pract Neurol 2021; 21:257-258. [PMID: 33462076 DOI: 10.1136/practneurol-2020-002809] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/31/2020] [Indexed: 11/04/2022]
Affiliation(s)
- Waqar Waheed
- Department of Neurology, University of Vermont Medical Center, Burlington, Vermont, USA
| | - Rup Tandan
- University of Vermont Medical Center, Burlington, Vermont, USA
| | - Michael Bazylewicz
- Department of Radiology, University of Vermont Medical Center, Burlington, Vermont, USA
| |
Collapse
|
4
|
Arsenijevic M, Berisavac I, Bozovic I, Stojiljkovic-Tamas O, Palibrk A, Lukic-Rajic S, Vujovic B, Peric S. Self-reported autonomic dysfunction in a recovery phase of Guillain-Barré syndrome. Clin Neurol Neurosurg 2020; 201:106427. [PMID: 33360355 DOI: 10.1016/j.clineuro.2020.106427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 12/06/2020] [Accepted: 12/07/2020] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Autonomic dysfunction occurs in approximately two-thirds of Guillain-Barré syndrome (GBS) patients in the acute phase of the disease. Although improving over time, subclinical autonomic involvement may be present for 3-8 years after the GBS episode. The aim of this study was to determine the frequency of self-reported autonomic disorders in GBS patients three and six months after disease onset compared to healthy controls (HCs). METHODS Our study included adult patients diagnosed with GBS from May 2017 until May 2018 in seven healthcare centers (67.6 % with demyelinating and 13.6 % with axonal syubtype). Functional disability was assessed by the Guillain-Barré syndrome disability scale (GDS). Each subject filled in the Serbian version of the SCOPA-Aut questionnaire. Using GDS and SCOPA-Aut, patients were tested at month 3 (M3) (n = 71) and month 6 (M6) (n = 70) from symptom onset. RESULTS Dysautonomia was more common in patients with GBS compared to HCs at M3 (p < 0.01), while there was no difference at M6 (p > 0.05). Among autonomic disorders, constipation, complications to pass stool, and orthostatic hypotension were the most frequently reported. Patients with axonal variants had worse total SCOPA-Aut scores at M3 in comparison to AIDP patients (11.7 ± 10.1 vs. 6.1 ± 5.1, p < 0.05). GDS score correlated with the total SCOPA-Aut score. CONCLUSION Autonomic symptoms are common in GBS patients during the recovery phase. They are more pronounced in patients with axonal forms of GBS and those with a higher degree of functional disability.
Collapse
Affiliation(s)
- Mirjana Arsenijevic
- Neurology Clinic, Clinical Center of Serbia, Dr Subotic Street 6, 11 000 Belgrade, Serbia
| | - Ivana Berisavac
- Neurology Clinic, Clinical Center of Serbia, Dr Subotic Street 6, 11 000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotic Street 8, 11 000 Belgrade, Serbia
| | - Ivo Bozovic
- Neurology Clinic, Clinical Center of Serbia, Dr Subotic Street 6, 11 000 Belgrade, Serbia
| | | | - Aleksa Palibrk
- Neurology Clinic, Clinical Center of Serbia, Dr Subotic Street 6, 11 000 Belgrade, Serbia
| | - Sonja Lukic-Rajic
- Neurology Clinic, Clinical Center of Vojvodina, Hajduk Veljkova Street 1-9, 21 000 Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia
| | - Balsa Vujovic
- Neurology Clinic, Clinical Center of Montenegro, Ljubljanska Street nn, 81 000 Podgorica, Montenegro
| | - Stojan Peric
- Neurology Clinic, Clinical Center of Serbia, Dr Subotic Street 6, 11 000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotic Street 8, 11 000 Belgrade, Serbia.
| |
Collapse
|
5
|
Kajumba MM, Kolls BJ, Koltai DC, Kaddumukasa M, Kaddumukasa M, Laskowitz DT. COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications. ACTA ACUST UNITED AC 2020; 2:2702-2714. [PMID: 33251483 PMCID: PMC7680081 DOI: 10.1007/s42399-020-00646-w] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/16/2020] [Indexed: 12/11/2022]
Abstract
The concurrence of COVID-19 with Guillain-Barre syndrome (GBS) can increase the likelihood of neuromuscular respiratory failure, autonomic dysfunction, and other life-threatening symptoms. Currently, very little is known about the underlying mechanisms, clinical course, and prognostic implications of comorbid COVID-19 in patients with GBS. We reviewed COVID-19-associated GBS case reports published since the outbreak of the pandemic, with a database search up to August 2020, including a manual search of the reference lists for additional relevant cases. Fifty-one (51) case reports of COVID-19 patients (aged 23–84 years) diagnosed with GBS in 11 different countries were included in this review. The results revealed atypical manifestations of GBS, including para-infectious profiles and onset of GBS without antecedent COVID-19 symptoms. Although all tested patients had signs of neuroinflammation, none had SARS-CoV-2 in the cerebrospinal fluid (CSF), and only four (4) patients had antiganglioside antibodies. The majority had a 1- to 10-day time interval between the onset of COVID-19 and GBS symptoms, and many had a poor outcome, with 20 out of the 51 (39.2%) requiring mechanical ventilation, and two deaths within 12 to 24 h. The atypical manifestations of COVID-19-associated GBS, especially the para-infectious profile and short time interval between the onset of the COVID-19 and GBS symptoms, increase the likelihood of symptom overlap, which can complicate the treatment and result in worsened disease progression and/or higher mortality rates. Inclusion of a neurological assessment during diagnosis of COVID-19 might facilitate timely identification and effective management of the GBS symptoms and improve treatment outcome.
Collapse
Affiliation(s)
- Mayanja M. Kajumba
- Department of Mental Health and Community Psychology, School of Psychology, Makerere University, P. O. Box, 7062 Kampala, Uganda
| | - Brad J. Kolls
- Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Duke University Medical Center, Box 3807, Durham, NC 27705 USA
- Department of Neurology, Duke University School of Medicine, Durham, NC USA
- Neuroscience Medicine, Duke Clinical Research Institute, 300 W Morgan St, Durham, NC 27701 USA
| | - Deborah C. Koltai
- Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Duke University Medical Center, Box 3807, Durham, NC 27705 USA
- Department of Neurology, Duke University School of Medicine, Durham, NC USA
- Department of Psychiatry and Behavioral Sciences, DUMC, Duke University School of Medicine, Box 3119, Trent Drive, Durham, NC USA
| | - Mark Kaddumukasa
- Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, P.O. Box 7072, Kampala, Uganda
| | - Martin Kaddumukasa
- Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, P.O. Box 7072, Kampala, Uganda
| | - Daniel T. Laskowitz
- Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Duke University Medical Center, Box 3807, Durham, NC 27705 USA
- Department of Neurology, Duke University School of Medicine, Durham, NC USA
- Neuroscience Medicine, Duke Clinical Research Institute, 300 W Morgan St, Durham, NC 27701 USA
| |
Collapse
|